| I. | Cardiovascular |
| Biochemical markers for myocardial damage (troponins, CK-MB) | |
| Biochemical markers of heart failure (BNP, NT-proBNP) | |
| Risk assessment (lipid testing, inflammatory markers, hsCRP, homocysteine) | |
| D-dimer | |
| National Cholesterol Education Program (NCEP) Guidelines | |
| II. | Endocrine |
| Diabetes - glucose point-of-care testing, HbA1c; Fructosamine; Blood glucose control in ICUs | |
| Thyroid – interpretation of thyroid panels, ultrasensitive TSH | |
| Adrenal – diagnosis of adrenal cortical hyperfunction (eg, Cushing’s, Conn’s) and hypofunction (eg. Addison’s, congenital adrenal hyperplasia); ACTH stim test to evaluate adrenal reserves in ICU; Salivary cortisol | |
| Interpretation of tests for pheochromocytoma (urine and serum catecholamines and metanephrines, VMA) | |
| Pituitary – testing for hormone-secreting pituitary tumors (especially prolactinomas), testing for selective or generalized pituitary gland failure | |
| Parathyroid - intraoperative PTH | |
| III. | Obstetric |
| Prenatal screen advances: first trimester testing/integrated 1st and 2nd trimester screening; dimeric inhibin A for Down syndrome detection (quad screening tests) | |
| Neonatal screening for most common metabolic diseases | |
| Fetal fibronectin for premature labor | |
| IV. | Urinary System |
| Microalbumin | |
| Use of estimating equations to predict glomerular filtration rate (eGFR) that use only measured serum creatinine and patient specific demographic factors (age, sex, race) to detect early renal disease | |
| V. | Electrolytes |
| Point-of-care testing | |
| Interpretation of anion gap (clinical and for QC) | |
| Interpretation of electrolyte abnormalities | |
| Osmolality; osmolar gap calculation (as surrogate for alcohol/methanol measurement) | |
| VI. | Markers for Neoplasia |
| CEA, AFP, CA 15-3/27.29, CA125, CA 19-9, total and free PSA, β-hCG | |
| her2/neu | |
| Work-up of suspected monoclonal gammopathy (serum free Ig light chain assays in the diagnosis of plasma cell dyscrasias, including AL) amyloidosis | |
| General interpretation of IFEs and SPEPs | |
| PSA role and limitations | |
| VII. | Nutrition and Anemia (overlap with Heme) |
| New testing methods for folate and B12 deficiency | |
| HPLC for hemoglobinopathies | |
| Iron overload disorders | |
| Thalassemia heterogeneity and lab diagnosis | |
| VIII. | Toxicology, New Drugs and Adulterants |
| Screening vs. confirmation for drugs of abuse | |
| Drugs of abuse masking agents | |
| Use of genetic tests to predict patient-specific pharmokinetic responses to drugs (i.e. pharmacogenetics/pharmacogenomics). example: warfarin metabolism and appropriate initial dosing | |
| TDM-sample timing relative to PK, common drugs, transplant Immunosuppression drug monitoring | |
| Principles of TDM | |
| IX. | Methodologies |
| Tandem mass spectroscopy-technology, common applications | |
| Electrophoresis—general interpretation of SPEPs and IFEs: e.g. IgG-specific isoelectric focusing for multiple sclerosis capillary zone electrophoresis | |
| HCV and cryoglobulin evaluation | |
| Immunosubtraction | |
| HbA1c limitations with hemoglobinopathies, eg sickle trait, HbC trait | |
| RAST | |
| General understanding of modern clinical laboratory instrumentation (e.g. spectrophotometry, ISE's, ELISA and RIA techniques, etc) | |
| Methods and method
interferences PCR/RT-PCR FISH HPLC ELISA Spectrophotometric analysis | |
| X. | Administration and Management |
| Point of Care testing |